Zcube

Hyivy Health specializes in developing an innovative pelvic rehabilitation device aimed at addressing the needs of women experiencing pelvic health complications, which affect one in three women globally. The company's device stands out by offering the first quantifiable data set on pelvic floor health, utilizing multiple biosensors and mechanical functions to deliver three distinct therapeutic approaches. This technology enables patients and their healthcare providers to monitor progress, adapt treatment plans, and enhance the overall rehabilitation experience. By integrating remote therapeutic and monitoring capabilities, Hyivy Health aims to improve the management of pelvic and gynecological conditions, providing a more effective and comfortable solution for patients.

Vilimed is a medical device development company that involves in the development of vibration tech which is a therapeutic device developed for hand tremor reduction.

Hyivy Health specializes in developing an innovative pelvic rehabilitation device aimed at addressing the needs of women experiencing pelvic health complications, which affect one in three women globally. The company's device stands out by offering the first quantifiable data set on pelvic floor health, utilizing multiple biosensors and mechanical functions to deliver three distinct therapeutic approaches. This technology enables patients and their healthcare providers to monitor progress, adapt treatment plans, and enhance the overall rehabilitation experience. By integrating remote therapeutic and monitoring capabilities, Hyivy Health aims to improve the management of pelvic and gynecological conditions, providing a more effective and comfortable solution for patients.

PharmEste s.r.l., a biopharmaceutical company, engages in the discovery and development of transient receptor potential (TRP) channel therapeutics for the treatment of neuropathic pain, overactive bladder, and other TRP-mediated diseases. It develops PHE377, a TRPV1 antagonist for the treatment of neuropathic pain.

ProtAffin is a biotechnology company in Austria developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures. ProtAffin's products are first-in-class engineered versions of human proteins which bind to cell surface glycans (sugars) to affect their biological activity. Activated versions of specific cell surface glycans underlie inflammatory processes in several diseases including rheumatoid arthritis, chronic obstructive pulmonary disorder, Crohn's disease and cancer and represent a rich and relatively under-investigated class of potential drug targets for the pharmaceutical and biotechnology industries. Protaffin's approach is entirely innovative and opens up glycans as druggable targets through the use of its CellJammer® discovery platform.

ProtAffin is a biotechnology company in Austria developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures. ProtAffin's products are first-in-class engineered versions of human proteins which bind to cell surface glycans (sugars) to affect their biological activity. Activated versions of specific cell surface glycans underlie inflammatory processes in several diseases including rheumatoid arthritis, chronic obstructive pulmonary disorder, Crohn's disease and cancer and represent a rich and relatively under-investigated class of potential drug targets for the pharmaceutical and biotechnology industries. Protaffin's approach is entirely innovative and opens up glycans as druggable targets through the use of its CellJammer® discovery platform.

SuppreMol is a private biotechnology company that specializes in developing therapeutics for autoimmune and allergic diseases. The company is dedicated to creating innovative treatments aimed at addressing the underlying causes of these disorders, rather than just alleviating their symptoms. SuppreMol's research focuses on soluble Fc-gamma receptors, which are recombinant autologous therapeutic proteins designed to possess specific immunoregulatory properties. This approach has the potential to advance the treatment landscape for individuals suffering from autoimmune conditions, offering new hope for more effective and long-lasting solutions.